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Background: Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial pneumonia causing a loss of respiratory
surface area due to a proliferative fibrotic response involving hyperplastic, hypertrophic, and metaplastic epithelium,
cystic honeycomb change, septal expansion, and variable inflammation. Wnt (wingless) signaling glycoproteins are
known to be involved in lung development and tissue repair, and are up-regulated in patients with IPF. Based on
previous qRT-PCR data showing increased Wnt7B in lungs of IPF patients, a systematic, quantitative examination of
its tissue site distribution was undertaken.
Methods: Tissue samples from the Lung Tissue Research Consortium (LTRC) of 39 patients diagnosed with mild to
severe IPF/usual interstitial pneumonia (UIP) and 19 normal patients were examined for the immunolocalization of
Wnt7B.
Results: In normal lung, moderate Wnt7B reactivity was confined to airway epithelium, smooth muscle of airways
and vasculature, and macrophages. IPF lung showed strong Wnt7B reactivity in fibroblastic foci, dysplastic airway
and alveolar epithelium, and in highly discrete subepithelial, basement membrane-associated regions. All reactive
sites were sized and counted relative to specific microscopic regions. Those in the subepithelial sites were found in
significantly greater numbers and larger relative area compared with the others. No reactive sites were present in
normal patient controls.
Conclusions: The results demonstrate Wnt7B to be expressed at high concentrations in regions of active
hyperplasia, metaplasia, and fibrotic change in IPF patients. In this context and its previously established biologic
activities, Wnt7B would be expected to be of potential importance in the pathogenesis of IPF.
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Idiopathic pulmonary fibrosis/usual interstitial pneumo-
nia (IPF/UIP) is a debilitating disease characterized by a
loss of normal respiratory architecture and replacement
with a heterogeneous population of myofibroblast-like
cells and excess of fibrous connective tissue restricted to
the lung [1,2]. IPF arises from inflammation in the
alveolar-capillary wall resulting in alveolar type I cell
(AT1) loss and AT2 cell hyperplasia and subepithelial/
interstitial fibrogenesis [3,4]. It has been suggested this
represents an attempt to repair the pulmonary barrier* Correspondence: philip_sannes@ncsu.edu
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reproduction in any medium, provided the orfollowing an injury to the respiratory surface [5]. The
hallmark lesions are fibroblastic foci, signifying active
disease, with a patchy mix of older fibrosis starting from
the subpleural surface and along interlobular septa. Early
lesions frequently appear highly cellular, with subepithe-
lial fibroblastic foci adjacent to normal pulmonary archi-
tecture [6,7]. In IPF the lesions lead to end-stage fibrosis
with minimal remaining pulmonary structure [6-8]. The
proposed pathogenesis centers on dysregulation of epi-
thelial repair in the form of hyperplastic and metaplastic
AT2 cells interrelated with fibroproliferative lesions and
aberrant epithelial differentiation, including epithelial to
mesenchymal transition (EMT) [8,9].
The signaling pathways involved are only partially
understood. It is known that there is increasedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(α-SMA) in progressive lesions of IPF reflecting the tran-
sition of fibroblasts to myofibroblasts with proliferation
and collagen maintenance modulated by wingless (Wnt)
glycoproteins [10-12]. Mouse models indicate cooper-
ation of TGF-β and Wnt signaling pathways in develop-
ment, differentiation, and EMT [13]. Altered expression
of Wnt ligands and one of their downstream targets, β-
catenin, is evident in early IPF and bleomycin models of
pulmonary fibrosis [14-16]. This can be explained in
light of up-regulated TGF-β by its induction of LEF-1,
which is a component of the canonical Wnt signaling
pathway [13]. Chilosi, et al., found highly concentrated
sites of β-catenin in myofibroblast-populated regions ad-
jacent to airways [14]. This correlated with elevated
mRNA expression and immunohistochemical reactivity
of Wnts 1 & 3a in adjacent pulmonary epithelium in IPF
patients [17]. Recent evidence shows that Wnt3a can ac-
tivate β-catenin-mediated signaling and induce EMT in
lung epithelial cells [18]. The collective views suggest
that canonical Wnt signaling (β-catenin mediated) is up-
regulated in fibrogenic conditions and may be causally
involved in IPF [16-19].
Wnt glycoproteins have been found to be expressed at
low levels in the normal lung and may be associated
with epithelial turnover [17,20]. For example, Wnt7B
mRNA expression in isolated normal AT2 cells was evi-
dent in low levels [17,21]. Wnt7b over-expression is
thought to be a contributing factor to fibrogenesis in the
murine kidney [22] and to be involved with procollagen
production by lung fibroblasts [12]. Wnt7b was of spe-
cial interest because of its role in mesenchymal prolifera-
tion and vascular development in the lung [23]. Based
on supporting qRT-PCR data showing increased Wnt7B
in lungs of IPF patients [17], a systematic, examination
of its localization in a cohort of 39 IPF lungs was under-
taken. Wnt7B expression was found in spindle cells and
extracellular matrix of virtually all fibroblastic foci and
in widely distributed, large numbers of discretely defined
regions of the subepithelial basement membrane zone.
These findings may provide useful clues relating to the
pathogenesis of IPF and present novel, potential targets
for detection and treatment.
Materials & methods
Immunostaining
Tissue blocks of formalin-fixed lung tissue samples were
obtained from the Lung Tissue Research Consortium
(LTRC). The samples had previously been placed into
three groups (see Table 1): group 1, with forced vital
capacities (FVCs) >80% (normal, or no specified major
or minor diagnosis, n = 19); group 2, with FVCs between
50-80% [major final clinical diagnosis as interstitial lung
disease (ILD, n = 20) and minor final clinical diagnosis asusual interstitial pneumonia (UIP)/idiopathic pulmonary
fibrosis (IPF)]; and group 3, with FVCs <50% (major
final clinical diagnosis of ILD and minor final clinical
diagnosis as UIP/IPF, n = 19). No other patient identifiers
were provided, and their anonymity and confidentiality
were preserved. The study was approved by the North
Carolina State University Institutional Review Board.
Blocks were further randomized and sections stained
with hematoxylin and eosin (H&E) and picrosirius red
(PSR) or Movat’s pentachrome stain for collagen. H&E
sections were examined by a Board Certified Pathologist
to independently confirm/reclassify initial clinical
diagnoses.
Sections were treated with citrate buffer for antigen
retrieval and treated with a polyclonal goat anti-Wnt7B
antibody [Santa Cruz Biotechnology, Inc. (sc26363, lot#
I0205, Santa Cruz, CA)] at a 1:100 dilution overnight
at 4°C, followed by peroxidase-labeled secondary anti-
bodies (Dako LSAB+, Dako Laboratories, Carpinteria,
CA) and Nova Red (Vector Laboratories, Burlingame,
CA). The Wnt7B antibody recognizes both precursor
and mature forms of human origin. Control samples
substituted normal goat serum for the primary anti-
body, or were pre-treated with 5% testicular hyaluroni-
dase (Sigma, Type 1-S, St. Louis, MO) for 30 minutes
at 37°C to release Wnt7B bound to extracellular matri-
ces [24], or treated with a competitive antibody-binding
Wnt7B peptide to the primary antibody incubation.
Sections were counterstained with methylene blue.
Selected sequential and non-sequential serial sections
were immunostained with anti-human smooth muscle
actin.Analysis of Reactive Sites
The entirety of each section was systematically evalu-
ated at 200X magnification through a calibrated ocular
grid, and the size of each Wnt7B reactive site was mea-
sured. They were divided into three major size categor-
ies: <50 μm2, 50–100 μm2, and >100 μm2; while their
histologic sites were separated into one of three regional
designations: 1) epithelium and underlying fibroblasts
with or without extracellular matrix (EF), 2) subepithe-
lial fibroblasts and ECM (SE) without epithelial staining
(included most fibroblastic foci), and 3) interstitial
fibroblasts and ECM (I) that were not directly subjacent
to an epithelial surface. The number of sites corre-
sponding to the respective categories was recorded. The
total surface area, as defined by the external border of
each tissue section, was determined using ImageJ (Na-
tional Institutes of Health, Bethesda, MD), and the per-
cent of the total area of each reactive site category
relative to the total section surface area was calculated
(see Table 1).
Table 1 Patient group data summary and total Wnt7B area reactivity












34/1 0 Normal 22/29 0.22660864 Mild IF 53/13 0.308239253 Mild IF
50/8 0 Normal 52/59 0.46500093 Mild IF 40/11 0.318122907 Mild IF
60/9 0 Normal 9/55 0.702668072 IPF 51/7 0.421600843 IPF/UIP
29/25 0 Normal 46/51 0.792223807 IPF 32/28 0.543860737 IPF/UIP
27/26 0 Normal 3/50 0.853712645 Severe IF 11/12 0.609837285 IPF/UIP
43/16 0 Normal 39/43 0.898132637 IPF/UIP 2/38 0.689568308 IPF/UIP
33/23 0 Normal 30/17 0.984128952 IPF/UIP 38/35 0.870788258 IPF/UIP
13/39 0 Mild emphysema 58/15 1.02457832 Mild IF 19/47 1.07500215 Mild IF
47/44 0 Normal 54/34 1.124896765 IPF/UIP 23/31 1.246080924 Inf/Honeycombing
31/45 0 Normal 12/19 1.127274982 Severe IF 48/53 1.332033914 Mild IF
20/46 0 Normal 55/5 1.135880134 Mild IF 35/10 1.451763467 IPF/UIP
28/49 0 Mild emphysema 15/4 1.19162088 Mild IF 16/21 1.506947458 IPF/UIP
5/52 0 Septal thickening 42/32 1.257089128 IPF/UIP 49/20 1.597695503 Mild IF
1/57 0 Normal 45/18 1.470515762 IPF/UIP 4/41 1.698264266 IPF/UIP
7/60 0 Normal 36/33 1.5500031 IPF/UIP 10/22 2.0666708 Mild IF
57/36 0 Mild emphysema 24/42 1.667114445 IPF/UIP 25/40 2.214.290 IPF/UIP
14/3 0.077500155 A telectasis/thickening 37/30 2.258029207 IPF/UIP 21/37 2.188697845 Mild IF
8/27 0.116043013 Normal 18/2 2.294004588 DIFFUSEIF 56/24 2.279055942 IPF/UIP
41/14 0.41333416 Normal 44/56 2.679444431 IPF/UIP 17/48 2.605680887 IPF/UIP
59/58 3.620364384 IPF/UIP
avg 0.031940912 avg 1.366149591 avg 1.267217264
stdev 0.097448895 stdev 0.808903868 stdev 0.71592836
Legend: IF – interstitial fibrosis; IPF – idiopathic pulmonary fibrosis; UIP – usual interstitial pneumonia.
Meuten et al. Respiratory Research 2012, 13:62 Page 3 of 10
http://respiratory-research.com/content/13/1/62Statistical analysis
Comparisons of the descriptive statistics of reactive sites
were made using Analysis of Variance or Kruskal-Wallis
non-parametric test for histologic locations in the same
reactive site groups and within lung capacity category
using SAS software (Cary, NC) or Minitab (Six Sigma,
State College, PA). For example, for patients in FVC 50-
80%, comparisons were made for reactive sites >100
(μm2) for EF, SE, and I locations. Statistical significance
was set at an alpha value of ≤ 0.05.
Results
Lungs with normal pulmonary architecture (group 1)
had weak to moderate Wnt7B immunoreactivity in the
cytoplasm of airway epithelium (ciliated cells) and
smooth muscle of airways and arteries (Figure 1a and
inset). Much weaker Wnt7B reactivity was evident in the
cytoplasm of AT2 cells (Figure 1a inset), alveolar macro-
phages, and endothelial cells. Lungs originally categor-
ized with ILD and UIP/IPF (by the LTRC) had intense
and discrete immunoreactive sites for Wnt7B that varied
in size and location. The largest sites correlated directly
with easily identifiable fibroblastic foci characteristic ofIPF, where staining was particularly intense in the extra-
cellular matrix (Figures 1b, 1e, 2b, 2c, 2e). All sites, re-
gardless of size and location, were unreactive with
normal goat serum controls (Figure 1c). Pretreatment of
sections with 5% hyaluronidase prior to immunostaining
for Wnt7B completely attenuated the intense extracellu-
lar matrix reactive sites seen in parallel sections, while
most cellular reactivity was retained and somewhat in-
tensified (Figure 1d). This was particularly true of
smooth muscle cells (data not shown). This increased
cellular staining is likely due to the antibody detection of
intracellular and cell surface-associated forms of the
antigen, which is glycosylated [25], and made more avail-
able by the digestion procedure.
Simultaneous treatment of sections with Wnt7B anti-
body and its competitive binding Wnt7B peptide dur-
ing the staining procedure resulted in significant
reduction in all reactive sites in parallel sections, par-
ticularly in sites with the most intense immunoreactiv-
ity (Figure 1e vs. 1f ), confirming the specificity of the
staining.
Even at lower magnifications, the Wnt7B reactive sites
were readily detectable, especially the fibroblastic foci
Figure 1 Section of normal human lung treated for the immunohistochemical localization of Wnt7B. Figure 1a at low power, airway (A)
epithelial cells and smooth muscle (double arrows) surrounding a nearby vessel (V) exhibit reactivity for Wnt7B. Inset of the airway shows Wnt7B
reactivity in ciliated cells (solid arrowtip), AT2 cell (single arrow), and smooth muscle (double arrows). The airway insert also shows and non-
reactive non-ciliated bronchiolar cell (solid arrowhead). Methylene blue counterstain. Bar = 100 μm; inset Bar = 30 μm. Figure 1b, Section of UIP/
IPF lung treated for the immunohistochemical localization of Wnt7B. Two large fibroblastic foci (FF) demonstrate strong extracellular reactivity.
Bar = 100 μm. Figure 1c, Serial section of UIP/IPF lung in Figure 1b treated with non-immune serum instead of the Wnt7B-specific antibody.
Fibroblastic foci (FF) lack selective staining for the antigen, but show light metachromasia with the methylene blue counterstain. Bar = 100 μm.
Figure 1d, Serial section of UIP/IPF lung in Figure 1b treated for the immunohistochemical localization of Wnt7B after being exposed for 30
minutes to hyaluronidase digestion. The same fibroblastic foci (FF) have lost the strong, extracellular reactivity seen in Figure 1b, while there is
enhanced cellular reactivity throughout the tissue, presumptively due to unmasking of intracellular, glycosylated Wnt7B. Methylene blue
counterstain. Bar = 100 μm. Figure 1e-f, Serial sections of UIP/IPF lung treated for the immunohistochemical localization of Wnt7B; the first
(e) without and second (f) with the antigenic blocking peptide simultaneously with the Wnt7B-specific antibody. The two positive fibroblastic
foci (FF) in (e) show diminished selective staining for Wnt7B in (f). Methylene blue counterstain. Bar = 100 μm.
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of three regional dispositions according to the criteria
described above: EF, SE (which included most fibroblas-
tic foci), and I (Figure 2b). Sequential and non-
sequential serial sections were used to compare Wnt7B
stained slides with those stained with H&E, picrosirius
red (PSR), Movat’s pentachrome, or immunohistochem-
istry for smooth muscle actin. Fibroblastic foci were eas-
ily detected by their large size (typically >100 μm2) and
strong extracellular reactivity for Wnt7B, with mostfound adjacent to thickened airways (Figure 2b-c) and
thickened interstitium in alveolar regions (1e, 2e). They
correlated well with sequential/non-sequential serial sec-
tions stained with H&E (data not shown) and penta-
chrome (2d, 2f ). The red reactivity of collagen with PSR
was very strong throughout IPF lungs, especially in
highly thickened areas of mature collagen and thickened
basal laminae (data not shown). Fibroblastic foci were
easily identifiable, mainly by virtue of their lighter stain-
ing, immature collagen content (as shown with the
Figure 2 Low power magnification of a section of UIP/IPF lung treated for the immunohistochemical localization of Wnt7B. Fibroblastic
foci are easy to identify (large arrows), as are even small reactive sites (small arrows). Methylene blue counterstain. Bar = 600 μm. Figure 2b,
Section of UIP/IPF lung treated for the immunohistochemical localization of Wnt7B demonstrating the three categories designated for sizing and
quantitation. Preliminary histopathologic evaluation of the slides determined that all reactive sites were confined to one of three characteristic
types: epithelial + fibroblast + extracellular matrix (EF), subepithelial (SE, fibroblast + extracellular matrix), or interstitial (I, not adjacent to epithelial
surfaces). Methylene blue counterstain. Bar = 100 μm. Figure 2c-f, Serial sections of UIP/IPF lung treated for the immunohistochemical
localization of Wnt7B (c, e) or Movat’s pentachrome (d, f) in airway (c, d) and alveolar (e. f) regions. The same fibroblastic foci (FF) stain clearly
with both treatments. Methylene blue counterstain. Bar = 100 μm. Figure 2g, Section of UIP/IPF lung treated for the immunohistochemical
localization of Wnt7B demonstrating reactivity of the mesothelial surface (arrows) and the subjacent cells and thickened interstitium. Methylene
blue counterstain. Bar = 100 μm.
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pearance (data not shown).
Wnt7B immunoreactivity was found both intra- and
extracellularly. Without hyaluronidase digestion, the
extracellular reactivity was discrete and intense and
found in the ECM regions of fibroblastic foci
(Figures 1b, 1e, 2b-c, 2f ), subepithelial ECM (Figure 2a-
b, 3b), and interstitium (Figure 2b) not adjacent to epi-
thelium. The sizes of the reactive sites varied widely,
with fibroblastic foci having the greatest individualreactive areas (often >1600 μm2; Figures 1b, 2c, 2b-c,
2e) and the SE regions being the most numerous and
smallest in individual reactive area (Figure 2b, 3a-d).
These smaller sites were not distinguishable by any mor-
phologic features or special staining characteristics (data
not shown). Intracellular reactivity was very intense in
some epithelia, especially that considered hyper- or
metaplastic (Figure 3a), and in fibroblasts of fibroblastic
foci, especially the larger SE sites (Figure 3c) and smaller
SE sites (Figure 3d). In airways, basal cells were often
Figure 3 Sections of UIP/IPF lung treated for the immunohistochemical localization of Wnt7B. Figure 3a demonstrates staining of
hypertrophic/metaplastic alveolar epithelial cells. Figure 3b demonstrates extensive subepithelial (SE, not an FF) site reactivity (arrows) around one
side of a small airway. Figure 3c demonstrates reactivity within a fibroblastic focus (FF) and adjacent SE sites (arrows). The inset at higher
magnification of the fibroblastic foci demonstrates the extracellular matrix and cellular (arrow) nature of the reactivity. Figure 3d demonstrates
extensive subepithelial (SE) site reactivity (arrows) around two small airways, the apparent reactivity of presumptive basal cells (arrows) within the
respective airways. The inset at higher magnification shows presumptive, reactive fibroblasts embedded within reactive matrix (arrowheads).
Methylene blue counterstain. Bars = 50 μm; inset bars = 30 μm.
Meuten et al. Respiratory Research 2012, 13:62 Page 6 of 10
http://respiratory-research.com/content/13/1/62reactive (Figure 3d), as were some ciliated cells (data not
shown). Mesothelium was generally positive, but meso-
thelial immunoreactivity was most intense when overly-
ing areas of interstitial fibrosis (Figure 2g). Macrophages
were variably reactive for Wnt7B, while other inflamma-
tory cells present in IPF/UIP lungs were uniformly nega-
tive (data not shown). Many SE sites reflected staining of
portions of basal lamina (Figures 3b-d) and/or strong
staining of fibroblasts within the subepithelial fibroblast
layer (Figure 3d). The fibroblastic component of Wnt7B-
positive fibroblastic foci (Figure 3d-e) was uniformly
positive for smooth muscle actin (Figure 3f ), reflective of
the myofibroblast phenotype.
Patients with FVC> 80% had few quantifiable Wnt7B
reactive sites (Figure 4a) compared to patients with func-
tional diagnoses of IPF/UIP [<80% (Figures 4b-c)].
There were insufficient reactive sites for the EF category
to compare to corresponding reactive SE and I regions.
Despite an outlier (defined as greater than 2 standard
deviations from the mean) for the SE region <50 μm2
category, the reactive sites for locations SE and I were
not statistically different, given that the median value
was 0 for all reactive sites by location. For patients withFVC 50-80% and FVC <50%, reactive site size means (in
μm2), standard deviations, and minimum, median, and
maximum sizes of reactive sites (in μm2) are presented
in Tables 2 and 3. For patients with FVC 50-80% and
FVC <50%, the means of the number of each of the re-
active site sizes for the SE location were statistically
greater than that of those for EF and I locations
(p< 0.05).
Discussion
The initiating cause(s) underlying the pathogenesis of
idiopathic pulmonary fibrosis (IPF) is unknown. Much
attention has focused on a failed repair of alveolar epi-
thelium, and its impact on subsequent loss of pulmonary
architecture. This failure manifests as the inability of
epithelial surfaces to proliferate and differentiate effect-
ively resulting in hyperplasia, metaplasia, and/or trans-
differentiation into myofibroblast-like cells [26]. Exactly
how these dysplastic events culminate, independently or
collectively, in the formation of one of the hallmarks of
IPF, the fibroblastic focus, is not clear. Studying the roles
that specific signaling pathways play in the complex pro-
cesses involved in the formation of fibroblastic foci has
Figures 4 (See legend on next page.)
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Figures 4 Distribution of the total Wnt7B reactivity at the EF, SE, and I site categories for patients with FVCs >80% (normal), 50-80%
(intermediate impairment), or <50% (severe impairment). Normal patients had minimal Wnt7B reactivity, most with a median total area
reactivity of “0” (a). Patients with impaired FVCs had many more reactive sites than controls, although those with intermediate and severe
impairment were not different (see Tables 2 and 3). Notably, the median of the mean total of reactivity was greatest in the SE sites that were
<50 μm² (b-c).
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tors, such as TGF-β, that not only promote the depos-
ition of excessive collagen but mediate the process of
EMT as well [10]. TGF-β has been immunohistochemi-
cally localized to alveolar epithelium and extracellular
matrix of IPF lungs [27] and is within fibroblastic foci
[28,29]. Fibroblastic foci are also rich in its downstream
nuclear targets like phospho-Smad 2/3 [28] and relevant
proteins, such as cysteine-rich protein 1 (CRP-1), which
is important in smooth muscle cell differentiation [30].
Relatedly, activated β-catenin has been shown to be up-
regulated in the nuclei of myofibroblasts of fibroblastic
foci of IPF patients [14], and alveolar epithelial responses
to TGF-β involve alpha3 integrin for β-catenin phos-
phorylation and formation of a β-catenin/p-Smad2 com-
plex resulting in initiation of EMT [31]. More
specifically, TGF-β-stimulated Smad3 has recently been
shown to form a complex with β-catenin and CREB-
binding protein in regulation of α-smooth muscle actin,
a cytologic signature of EMT [32]. SPARC (secreted pro-
tein acidic rich in cysteine), an extracellular matrix com-
ponent abundant in fibroblastic foci [33], should also be
noted, as it has been shown to activate AKT, inhibit
GSK-3β, and activate β-catenin, resulting in an anti-
apoptotic phenotype [34], another characteristic of the
IPF myofibroblast. [10-12].
The finding of strong Wnt7B immunoreactivity in the
fibroblastic focus of UIP/IPF lungs would seem to fit
readily with the above discussion on canonical Wnt sig-
naling involving β-catenin. The demonstration of Wnt7B
in dysplastic airway and alveolar epithelium and in myo-
fibroblasts of the fibroblastic foci closely correlates withTable 2 Patients with FVC>50%<80%
Site/size Mean StDev Min Med Max
EF> 100 0.02098 0.03446 0 0.00906 0.14388
EF >50< 100 0.01925 0.03713 0 0.00829 0.17004
EF <50 0.0427 0.0477 0 0.0181 0.1653
SE >100 *0.198 0.1508 0 0.1613 0.5167
SE >50< 100 *0.194 0.1715 0 0.1575 0.7086
SE <50 *0.675 0.562 0 0.537 2.38
I >100 0.02319 0.04121 0 0.00829 0.186
I >50< 100 0.0231 0.02473 0 0.01027 0.08267
I <50 0.1044 0.152 0 0.0458 0.6613the site localization of active β-catenin in IPF lungs [14].
However, that study did not report active β-catenin in
fibroblasts/myofibroblasts in regions other than fibro-
blastic foci. Wnt7B localization, demonstrated here, was
also clearly defined in a large number of smaller sites
(<50 μm2) that, like fibroblastic foci, had both cellular
and extracellular matrix components. The loss of extra-
cellular Wnt7B immunoreactivity after hyaluronidase di-
gestion supports the matrix-associated localization,
which is not surprising, as Reichsman, et al., [24] have
demonstrated that most secreted Wnts (approximately
83%) are bound to the cell surface and surrounding
extracellular matrix through specific, non-covalent inter-
actions. The localization of Wnt7B in fibroblastic foci
and a large number of smaller subepithelial sites position
it well for influencing the activity of the underlying
interstitium. In normal lung development, murine
Wnt7b has been shown to be exclusively expressed in
epithelial cells and regulated by TTF-1, GATA-6, and
FoxA2 [35]. In the embryo, it has been demonstrated to
stimulate epithelial and mesenchymal proliferation, likely
through its activation of BMP-4 and Id2 [36]. Further,
Wnt7b/β-catenin signaling regulates a program of mes-
enchymal cell differentiation and proliferation that is ne-
cessary for smooth muscle cell development in
cooperation with tenascin-C and involving PDGFR-alpha
and PDGFR-beta [37]. It may not be surprising, then,
that similar genetic programs are reactivated in some
form in an adult disease such as IPF, in which tenascin-
C is heavily expressed in the matrix of fibroblastic fociTable 3 Patients with FVC<50%
Site/size Mean StDev Min Med Max
EF >100 0.02615 0.02849 0 0.0159 0.10568
EF >50< 100 1.02039 0.02286 0 0.01761 0.07789
EF <50 0.04478 0.03933 0 0.04559 0.124
SE >100 *0.1589 0.03933 0.00677 0.131 0.4524
SE >50< 100 *0.2121 0.167 0.0124 0.1976 0.6228
SE <50 *0.7170 0.477 0.0352 0.755 1.654
I >100 0.01564 0.02594 0 0.0124 0.11683
I >50< 100 0.02883 0.03709 0 0.02067 0.15578
I <50 0.093 0.1135 0 0.0671 0.4284
* the means of the number of each of the reactive site sizes for the SE
location were statistically greater than that of those for EF and I locations
(p< 0.05).
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located [38]. Coupled with the strong expression of
Wnt7B in hyperplastic/metaplastic epithelium and fibro-
blastic foci reported here, these observations support
previous conclusions that epithelium in IPF may be re-
sponsible for aberrant activation of Wnt signaling, such
as that of Wnt7B, in adjacent mesenchyme, leading to
damage to the lung and fibrosis [19].
The notion that Wnt7B may have a potentially con-
tributive if not significant role in the development and/
or progression of IPF draws on previous assumptions
that the fibroblastic foci are central to the disease
process and its prognosis [39,40]. The fibroblastic foci
were the most dramatic sites of Wnt7B localization
observed in the IPF lung specimens. However, when sys-
tematically categorized and analyzed relative to location
and size, the Wnt7B reactive sites of large fibroblastic
foci were not the most numerous nor did they consume
the greatest percentage of total tissue section area, re-
gardless of disease severity according to % FVC, assum-
ing the section samples correctly reflected the overall
extent of fibrotic change of the whole lung (see Figure 4).
This distinction belonged to the small subepithelial (SE)
sites <50 μm2 (Figures 1d, 2a, 3b-d). These unique re-
active sites had no other morphological features that
were specifically distinguishing other than their discrete
Wnt7B immunoreactivity. In parallel sections, the small
SE sites, like the larger fibroblastic foci, consistently con-
tained abundant cells expressing the myofibroblast
phenotype, as indicated by α-smooth muscle actin
immunoreactivity (Figure 3f ), but by virtue of their
Wnt7B reactivity, clearly represented a subpopulation of
these cells compared with the overall total myofibroblast
population in IPF lungs. While it is not clear from the
current data that there are any connections between the
Wnt7B positive reactivity of the fibroblastic foci and the
more numerous, smaller SE sites, Cool, et al., [41]
demonstrated with three-dimensional reconstruction of
pentachrome-stained sections that fibroblastic foci of
UIP form a complex, interconnected network that
extends from the pleura into the parenchyma. Perhaps
the strong reactivity for Wnt7B within fibroblastic foci,
shown here to correlate precisely with pentachrome re-
activity, along with the foci’s complement of established
pro-fibrogenic components constitute the expansion
unit of IPF, and the small Wnt7B-positive, subepithelial
(SE) sites are the leading edge of this process. The loca-
tion of the small SE sites could portend the epithelial-
fibroblast cross-talk often involving Wnt signaling and
known to be important determinants of the fibrogenic
events characteristic of IPF [26]. The regionally confined
localization of Wnt7B differs from that of Wnt5A, which
is strongly expressed in the majority of fibroblasts
derived from UIP patients (i.e., almost all of theremaining fibroblasts), and shown to signal through
non-canonical pathways, promote proliferation, and pre-
vent apoptosis [42]. It raises the possibility that Wnt7B
and Wnt5A, along with TGF-β, SPARC, and tenascin-C,
work in some coordinated or concerted fashion to
modulate fibroblast/myofibroblast activities in adjacent
and/or different anatomic regions of IPF lungs. Extensive
and more detailed studies are currently underway to
help develop a better understanding of this complex
process.
Conclusions
These observations draw attention to a specific Wnt sig-
naling ligand, Wnt7B, which by virtue of its established
roles in epithelial and mesenchymal proliferation and
differentiation, procollagen production, and enhanced
gene expression in IPF, would be expected to act as a
significant contributor to the pathogenesis of IPF. This
is supported not only by the strong expression of Wnt7B
in fibroblastic foci but also by the numerous, small sube-
pithelial sites that may represent early stages of develop-
ing fibroblastic foci as part of a larger, expanding
network of fibrogenic tissue.
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